Home › Companies › Filana Therapeutics, Inc. › 2025-2026

Filana Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Filana Therapeutics, Inc.’s Form 8-K, filed 2026-06-15 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
104Asset managers
357Fund votes
2026-06-11Meeting date

Proxy season: 2025-2026

Explore Filana Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Filana Therapeutics, Inc.

These tallies are Filana Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-15 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Filana Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-11
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Richard J. Barry	8,851,285	--	--	1,564,191	14,144,300	Majority: yes
Elect Director: Pierre Gravier	9,069,595	--	--	1,345,881	14,144,300	Majority: yes
Elect Director: Claude Nicaise, M.D.	8,924,355	--	--	1,491,121	14,144,300	Majority: yes
Proposal Two – An amendment to the Company's 2018 Omnibus Incentive Plan was approved based upon the following votes:	8,427,565	1,869,290	118,621	--	14,144,300	Majority: yes
Proposal Four – The 2025 executive compensation for the Company's named executive officers was approved, on a non-binding advisory vote, based upon the following votes:	7,487,142	2,827,840	100,494	--	14,144,300	Majority: yes

Source: Filana Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-15 — read the filing on EDGAR.

How asset managers voted at the Filana Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 104 asset managers that disclosed a Filana Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Filana Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, BY A NON-BINDING ADVISORY VOTE, 2025 EXECUTIVE COMPENSATION FOR THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%AGAINST 27%

FOR: 7,487,142AGAINST: 2,827,840

Filana Therapeutics, Inc.’s own tally for this item (“Proposal Four – The 2025 executive compensation for the Company's named executive officers was approved, on a non-binding advisory vote, based upon the following votes:”): 7,487,142 for, 2,827,840 against, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,297,000 outstanding shares: 16% for, 6% against (21% of the company cast a for/against vote).

The 104 asset managers below cast 85% of the shares they voted on this item FOR (5,783,923 for, 999,813 against).

FOR 85%AGAINST 15%

FOR: 5,783,923 (85.3%)AGAINST: 999,813 (14.7%)ABSTAIN: 201 (0.0%)

Largest asset managers voting on “TO APPROVE, BY A NON-BINDING ADVISORY VOTE, 2025 EXECUTIVE COMPENSATION FOR THE COMPANY'S NAMED EXECUTIVE OFFI” at Filana Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	2,294,918	2,304	1	For
BlackRock	776,988	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	608,564	0	0	For
Fidelity	506,284	0	0	For
Two Sigma	472,312	0	0	For
MARSHALL WACE, LLP	0	376,656	0	Against
GMT CAPITAL CORP	0	375,346	0	Against
ACADIAN ASSET MANAGEMENT LLC	206,150	0	0	For
CANADA PENSION PLAN INVESTMENT BOARD	189,100	0	0	For
Dimensional	0	105,914	0	Against
DE Shaw	102,136	0	0	For
Goldman Sachs	94,708	0	0	For
T. Rowe Price	94,104	0	0	For
Northern Trust	84,915	0	0	For
Federated Hermes	81,746	0	0	For
Connor, Clark & Lunn Investment Management Ltd.	70,551	0	0	For
Charles Schwab	0	50,000	0	Against
MELLON INVESTMENTS Corp	40,754	0	0	For
Cerity Partners LLC	0	35,000	0	Against
American Century	26,816	0	0	For
PNC BANK, NATIONAL ASSOCIATION	0	22,591	0	Against
State Street	21,457	0	0	For
Invesco	0	14,460	0	Against
JOHNSON INVESTMENT COUNSEL INC	12,000	0	0	For
STIFEL NICOLAUS & CO INC \MO\	10,651	0	0	For

Showing the 25 largest of 104 asset managers. See all 104 in the interactive database.

2. To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are duly elected and qualified: Claude Nicaise, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%WITHHELD 14%

FOR: 8,924,355WITHHELD: 1,491,121

Filana Therapeutics, Inc.’s own tally for this item (“Elect Director: Claude Nicaise, M.D.”): 8,924,355 for, 1,491,121 withheld, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,297,000 outstanding shares: 18% for, 3% withheld (22% of the company cast a for/withheld vote).

The 15 asset managers below cast 100% of the shares they voted on this item FOR (2,710,290 for, 0 against).

FOR 99%

FOR: 2,710,290 (98.8%)ABSTAIN: 31,936 (1.2%)

Largest asset managers voting on “To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are” at Filana Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	1,992,398	7	For
Fidelity	501,287	0	For
Dimensional	81,961	0	For
BlackRock	62,003	0	For
Goldman Sachs	28,701	0	For
Charles Schwab	0	25,000	Abstain
American Century	13,408	0	For
Blackstone Alternative Investment Funds	10,600	0	For
Invesco	7,230	0	For
Equitable	7,177	0	For
Northern Trust	0	6,697	Abstain
Victory Capital	4,877	0	For
Guggenheim	448	0	For
Advisors' Inner Circle Fund III	0	232	Abstain
MARCO INVESTMENT MANAGEMENT LLC	200	0	For

3. To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are duly elected and qualified: Pierre Gravier

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 9,069,595WITHHELD: 1,345,881

Filana Therapeutics, Inc.’s own tally for this item (“Elect Director: Pierre Gravier”): 9,069,595 for, 1,345,881 withheld, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,297,000 outstanding shares: 19% for, 3% withheld (22% of the company cast a for/withheld vote).

The 15 asset managers below cast 100% of the shares they voted on this item FOR (2,742,220 for, 0 against).

FOR 99.9%

FOR: 2,742,220 (100.0%)ABSTAIN: 6 (0.0%)

Largest asset managers voting on “To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are” at Filana Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	1,992,399	6	For
Fidelity	501,287	0	For
Dimensional	81,961	0	For
BlackRock	62,003	0	For
Goldman Sachs	28,701	0	For
Charles Schwab	25,000	0	For
American Century	13,408	0	For
Blackstone Alternative Investment Funds	10,600	0	For
Invesco	7,230	0	For
Equitable	7,177	0	For
Northern Trust	6,697	0	For
Victory Capital	4,877	0	For
Guggenheim	448	0	For
Advisors' Inner Circle Fund III	232	0	For
MARCO INVESTMENT MANAGEMENT LLC	200	0	For

4. To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are duly elected and qualified: Richard J. Barry

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 8,851,285WITHHELD: 1,564,191

Filana Therapeutics, Inc.’s own tally for this item (“Elect Director: Richard J. Barry”): 8,851,285 for, 1,564,191 withheld, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,297,000 outstanding shares: 18% for, 3% withheld (22% of the company cast a for/withheld vote).

The 15 asset managers below cast 100% of the shares they voted on this item FOR (2,737,359 for, 0 against).

FOR 99.8%

FOR: 2,737,359 (99.8%)ABSTAIN: 4,867 (0.2%)

Largest asset managers voting on “To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are” at Filana Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	1,987,770	4,635	For
Fidelity	501,287	0	For
Dimensional	81,961	0	For
BlackRock	62,003	0	For
Goldman Sachs	28,701	0	For
Charles Schwab	25,000	0	For
American Century	13,408	0	For
Blackstone Alternative Investment Funds	10,600	0	For
Invesco	7,230	0	For
Equitable	7,177	0	For
Northern Trust	6,697	0	For
Victory Capital	4,877	0	For
Guggenheim	448	0	For
Advisors' Inner Circle Fund III	0	232	Abstain
MARCO INVESTMENT MANAGEMENT LLC	200	0	For

5. TO APPROVE AMENDMENT NO. 2 TO THE COMPANY'S 2018 OMNIBUS INCENTIVE PLAN, WHICH, AMONG OTHER THINGS, INCREASES THE AUTHORIZED NUMBER OF SHARES ISSUABLE THEREUNDER BY 4,000,000 SHARES (FROM 5,000,000 TO 9,000,000 AUTHORIZED SHARES).

COMPENSATIONMajority of the votes cast: yes

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%

FOR: 8,427,565AGAINST: 1,869,290

Filana Therapeutics, Inc.’s own tally for this item (“Proposal Two – An amendment to the Company's 2018 Omnibus Incentive Plan was approved based upon the following votes:”): 8,427,565 for, 1,869,290 against, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,297,000 outstanding shares: 17% for, 4% against (21% of the company cast a for/against vote).

The 15 asset managers below cast 98% of the shares they voted on this item FOR (2,696,546 for, 46,980 against).

FOR 98%

FOR: 2,696,546 (98.3%)AGAINST: 46,980 (1.7%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “TO APPROVE AMENDMENT NO. 2 TO THE COMPANY'S 2018 OMNIBUS INCENTIVE PLAN, WHICH, AMONG OTHER THINGS, INCREASES ” at Filana Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	1,987,766	4,639	1	For
Fidelity	501,287	0	0	For
Dimensional	81,961	0	0	For
BlackRock	62,003	0	0	For
Goldman Sachs	0	28,701	0	Against
Charles Schwab	25,000	0	0	For
American Century	0	13,408	0	Against
Blackstone Alternative Investment Funds	10,600	0	0	For
Invesco	7,230	0	0	For
Equitable	7,177	0	0	For
Northern Trust	6,697	0	0	For
Victory Capital	4,877	0	0	For
UNITED CAPITAL FINANCIAL ADVISORS, LLC	1,500	0	0	For
Guggenheim	448	0	0	For
Advisors' Inner Circle Fund III	0	232	0	Against

6. TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 14 asset managers below cast 99.9% of the shares they voted on this item FOR (2,739,511 for, 2,514 against).

FOR: 2,739,511 (99.9%)AGAINST: 2,514 (0.1%)

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMP” at Filana Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	1,990,122	2,282	For
Fidelity	501,287	0	For
Dimensional	81,961	0	For
BlackRock	62,003	0	For
Goldman Sachs	28,701	0	For
Charles Schwab	25,000	0	For
American Century	13,408	0	For
Blackstone Alternative Investment Funds	10,600	0	For
Invesco	7,230	0	For
Equitable	7,177	0	For
Northern Trust	6,697	0	For
Victory Capital	4,877	0	For
Guggenheim	448	0	For
Advisors' Inner Circle Fund III	0	232	Against

Largest Filana Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Filana Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 48,297,000 shares outstanding at the time of that meeting.

Top Filana Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	4.76%
2	BlackRock	1.61%
3	GEODE CAPITAL MANAGEMENT, LLC	1.26%
4	Fidelity	1.05%
5	Two Sigma	0.98%
6	MARSHALL WACE, LLP	0.78%
7	GMT CAPITAL CORP	0.78%
8	ACADIAN ASSET MANAGEMENT LLC	0.43%
9	CANADA PENSION PLAN INVESTMENT BOARD	0.39%
10	Dimensional	0.22%

Reported Filana Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Filana Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	4.92%	13F
Two Sigma	4.12%	13F
BlackRock	2.93%	13F
Richard J. Barry	2.52%	DEF14A
Geode Capital	1.23%	13F
D.E. Shaw	1.16%	13F
Renaissance Technologies	0.68%	13F
Citadel Advisors	0.64%	13F
State Street	0.50%	13F
Dimensional Fund Advisors	0.50%	13F

Percentages above are of 48,297,000 shares outstanding, as reported by Filana Therapeutics, Inc. on its Form 10-K dated 2025-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Filana Therapeutics, Inc.’s 10-K dated 2025-12-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Filana Therapeutics, Inc.'s shareholder meeting held 2026-06-11, in the 2025-2026 proxy season, 104 asset managers reported how they voted in their SEC Form N-PX filings, covering 357 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, BY A NON-BINDING ADVISORY VOTE, 2025 EXECUTIVE COMPENSATION FOR THE COMPANY'S NAMED… — FOR was 73% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Filana Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-15.

Filana Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).